CA2223625A1 - Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors - Google Patents

Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Info

Publication number
CA2223625A1
CA2223625A1 CA002223625A CA2223625A CA2223625A1 CA 2223625 A1 CA2223625 A1 CA 2223625A1 CA 002223625 A CA002223625 A CA 002223625A CA 2223625 A CA2223625 A CA 2223625A CA 2223625 A1 CA2223625 A1 CA 2223625A1
Authority
CA
Canada
Prior art keywords
glycogen phosphorylase
indole
amides
carbonyl
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002223625A
Other languages
French (fr)
Other versions
CA2223625C (en
Inventor
Bernard Hulin
Dennis J. Hoover
Judith L. Treadway
William H. Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc.
Bernard Hulin
Dennis J. Hoover
Judith L. Treadway
William H. Martin
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US08/952,668 priority Critical patent/US6297269B1/en
Priority to DE69522718T priority patent/DE69522718T2/en
Priority to SK720-96A priority patent/SK72096A3/en
Priority to PCT/IB1995/000443 priority patent/WO1996039385A1/en
Priority to DK95918718T priority patent/DK0832066T3/en
Priority to EP95918718A priority patent/EP0832066B1/en
Priority to APAP/P/1996/000817A priority patent/AP9600817A0/en
Priority to CA002223625A priority patent/CA2223625C/en
Priority to APAP/P/1996/000816A priority patent/AP624A/en
Priority to MX9709874A priority patent/MX9709874A/en
Priority to AT95918718T priority patent/ATE205477T1/en
Application filed by Pfizer Inc., Bernard Hulin, Dennis J. Hoover, Judith L. Treadway, William H. Martin filed Critical Pfizer Inc.
Priority to ES95918718T priority patent/ES2161291T3/en
Priority to PT95918718T priority patent/PT832066E/en
Priority to JP09500245A priority patent/JP3068200B2/en
Priority to IS4345A priority patent/IS1846B/en
Priority to IL11823696A priority patent/IL118236A0/en
Priority to HU9601285A priority patent/HUP9601285A3/en
Priority to MA24241A priority patent/MA23874A1/en
Priority to SI9600163A priority patent/SI9600163A/en
Priority to TNTNSN96075A priority patent/TNSN96075A1/en
Priority to DZ960079A priority patent/DZ2036A1/en
Priority to BR9602626A priority patent/BR9602626A/en
Priority to BG100635A priority patent/BG62566B1/en
Priority to LVP-96-173A priority patent/LV11614B/en
Priority to PL96314603A priority patent/PL314603A1/en
Priority to RU96111013/14A priority patent/RU2159613C2/en
Priority to YU34796A priority patent/YU34796A/en
Priority to ZA9604646A priority patent/ZA964646B/en
Priority to AU54753/96A priority patent/AU700887B2/en
Priority to CZ19961627A priority patent/CZ289233B6/en
Priority to NO962322A priority patent/NO307335B1/en
Priority to SG1996009975A priority patent/SG45481A1/en
Priority to NZ286736A priority patent/NZ286736A/en
Priority to HR960266A priority patent/HRP960266B1/en
Priority to OA60836A priority patent/OA10459A/en
Priority to TR96/00478A priority patent/TR199600478A1/en
Priority to CO96029520A priority patent/CO4700453A1/en
Priority to TW085107435A priority patent/TW450961B/en
Publication of CA2223625A1 publication Critical patent/CA2223625A1/en
Priority to FI974437A priority patent/FI974437A/en
Priority to GR20010401947T priority patent/GR3037075T3/en
Priority to CN02106667A priority patent/CN1374082A/en
Application granted granted Critical
Publication of CA2223625C publication Critical patent/CA2223625C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

This invention relates to certain indole-2-carboxamides of formula (I) and the pharmaceutically acceptable salts and prodrugs thereof, wherein R6 is carboxy, (C1-C8)alkoxycarbonyl, C(O)NR8R9 or C(O)R12, useful as inhibitors of glycogen phosphorylase, methods of treating glycogen phosphorylase dependent diseases or conditions with such compounds and pharmaceutical compositions comprising such compounds.
CA002223625A 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors Expired - Fee Related CA2223625C (en)

Priority Applications (41)

Application Number Priority Date Filing Date Title
AT95918718T ATE205477T1 (en) 1995-06-06 1995-06-06 SUBSTITUTED N-(INDOLE-2-CARBONYL)-AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS
ES95918718T ES2161291T3 (en) 1995-06-06 1995-06-06 N- (INDOL-2-CARBONIL) AMIDAS AND DERIVATIVES AS INHIBITORS OF THE GLUCOGENO FOSFORILASA.
DE69522718T DE69522718T2 (en) 1995-06-06 1995-06-06 SUBSTITUTED N- (INDOL-2-CARBONYL) AMIDES AND DERIVATIVES AS GLYCOGEN PHOSPHORYLASE INHIBITORS
EP95918718A EP0832066B1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
APAP/P/1996/000817A AP9600817A0 (en) 1995-06-06 1995-06-06 Novel cryatal form of anhydrous 7-( [1A,5A,6A]-6-amino3-3-azabicyclo [3.1.0.] hex-3-yl) -6-fluro-1-(2,4-difluorophenyl)-1,4-dihydro-4-oxo-1, 8-naphthyridine-3-carboxylic acid, methanesulfonic acid salt.
CA002223625A CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
APAP/P/1996/000816A AP624A (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl)-b- alanimamides and derivatives as antidiabetic agents.
MX9709874A MX9709874A (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors.
US08/952,668 US6297269B1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
DK95918718T DK0832066T3 (en) 1995-06-06 1995-06-06 Substituted N- (indole-2-carbonyl) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PT95918718T PT832066E (en) 1995-06-06 1995-06-06 N-SUBSTITUTED- (INDOLE-2-CARBONYL) -AMIDES AND DERIVATIVES AS GLYCOGENE-PHOSPHORYLASE INHIBITORS
JP09500245A JP3068200B2 (en) 1995-06-06 1995-06-06 Substituted N- (indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
SK720-96A SK72096A3 (en) 1995-06-06 1995-06-06 Indole-2-carboxamides, glycogen phosphorylase inhibitors and pharmauceutical compositions
IS4345A IS1846B (en) 1995-06-06 1996-05-13 Substituted N- (indole-2-carbonyl) -b-alaninamide, their use and drug formulations
IL11823696A IL118236A0 (en) 1995-06-06 1996-05-13 Substituted N-(indole-2-carbonyl)-beta-alanimamides and derivatives as antidiabetic agents
HU9601285A HUP9601285A3 (en) 1995-06-06 1996-05-14 Substituted n-(indole-2-carbonyl)-beta-alaninamides and derivatives and pharmaceutical compositions containing them
MA24241A MA23874A1 (en) 1995-06-06 1996-05-15 N- (INDOLE-2-CARBONYL) - SUBSTITUTED BETA- ALANINAMIDES AND THEIR DERIVATIVES AS ANTIDIABETIC AGENTS
TNTNSN96075A TNSN96075A1 (en) 1995-06-06 1996-05-17 N- (INDOLE-2-CARBONYL) - SUBSTITUTED BETA- ALANINAMIDES AND DERIVATIVES THEREOF AS ANTIDIABETIC AGENTS
SI9600163A SI9600163A (en) 1995-06-06 1996-05-17 Substituted n-(indole-2-carbonyl)-beta-alanimamides and derivatives as antidiabetic agents
DZ960079A DZ2036A1 (en) 1995-06-06 1996-05-22 N- (indole-2-carbonyl) -beta-alaninamides substituted and their derivatives, serving as anti-diabetic agents.
BG100635A BG62566B1 (en) 1995-06-06 1996-06-04 Substituted n-(indol-2-carbonyl)- -alanineamides substituted n-(indol-2-carbonyl)- -alanineaimides and their derivatives as antidiabetic formulationand their derivatives as antidiabetic formulationss
LVP-96-173A LV11614B (en) 1995-06-06 1996-06-04 Substituted n-(indole-2-carbonyl)-©-alaninamides and derivatives as antidiabetic agents
PL96314603A PL314603A1 (en) 1995-06-06 1996-06-04 Substituted n-(indolo-2-carbonyl)-beta-alaninamides and their derivatives as antidiabetic agents
BR9602626A BR9602626A (en) 1995-06-06 1996-06-04 Compound method for the treatment of a disease or condition dependent on glycogen phosphorylase Method to prevent ischemic injury of the myocardium Pharmaceutical composition and process for the preparation of a compound
YU34796A YU34796A (en) 1995-06-06 1996-06-05 Substituted n-(indole-2-carbonyl)-î²alaninamides, derivatives thereof and pharmaceutical compositions containing them
ZA9604646A ZA964646B (en) 1995-06-06 1996-06-05 Substituted N-(indole-2-Carbonyl)-ß-alanimamides and derivatives as antidiabetic agents.
AU54753/96A AU700887B2 (en) 1995-06-06 1996-06-05 Substituted N-(indole-2-carbonyl)-beta-alanimamides and derivatives as antidiabetic agents
CZ19961627A CZ289233B6 (en) 1995-06-06 1996-06-05 Indole-2-carboxamides and pharmaceutical preparations based thereon
NO962322A NO307335B1 (en) 1995-06-06 1996-06-05 Substituted N- (indole-2-carbonyl) - <beta> -alaninamides, their use and pharmaceutical preparation
SG1996009975A SG45481A1 (en) 1995-06-06 1996-06-05 Substituted n-(indole-2-carbonyl)-b-alanimamides and derivatives as antidiabetic agents
NZ286736A NZ286736A (en) 1995-06-06 1996-06-05 N-(Indole-2-carbonyl) beta-amino acid derivatives and medicaments
RU96111013/14A RU2159613C2 (en) 1995-06-06 1996-06-05 Substituted n-(indole-2-carbonyl)-beta-alanylamides and their derivatives, method of treating glycogenphosphorylazo-dependent diseases, method for preventing ischemic myocardium damages, and pharmaceutical compositions
OA60836A OA10459A (en) 1995-06-06 1996-06-06 Substituted n-(indole-2-carbonyl)-beta-alanimamides and derivatives as antidiabetic agents
TR96/00478A TR199600478A1 (en) 1995-06-06 1996-06-06 Substituted N- (indole-2-carbonyl) -B-alanimamides and derivatives as antidiabetic agents.
HR960266A HRP960266B1 (en) 1995-06-06 1996-06-06 Substituted n-(indole-2-carbonyl-)amides and derivatives as antidiabetic agents
CO96029520A CO4700453A1 (en) 1995-06-06 1996-06-06 N- (INDOL-2-CARBONIL) -beta-ALANILAMIDAS SUBSTITUTED AND DERIVATIVES AS ANTI-DIABETIC AGENTS
TW085107435A TW450961B (en) 1995-06-06 1996-06-19 Substituted N-(indole-2-carbonyl)-β-alanimamides and derivatives as antidiabetic agents
FI974437A FI974437A (en) 1995-06-06 1997-12-05 Substituted N- (indole-2-carbonyl) amides and derivatives as glycogen phosphorylase inhibitors
GR20010401947T GR3037075T3 (en) 1995-06-06 2001-10-30 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
CN02106667A CN1374082A (en) 1995-06-06 2002-03-05 Use of glycogen sulphofoenzyme inhibitor

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CA002223625A CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
PCT/IB1995/000443 WO1996039385A1 (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Publications (2)

Publication Number Publication Date
CA2223625A1 true CA2223625A1 (en) 1996-12-12
CA2223625C CA2223625C (en) 2003-06-03

Family

ID=25679897

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002223625A Expired - Fee Related CA2223625C (en) 1995-06-06 1995-06-06 Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors

Country Status (40)

Country Link
US (1) US6297269B1 (en)
EP (1) EP0832066B1 (en)
JP (1) JP3068200B2 (en)
CN (1) CN1374082A (en)
AP (2) AP624A (en)
AT (1) ATE205477T1 (en)
AU (1) AU700887B2 (en)
BG (1) BG62566B1 (en)
BR (1) BR9602626A (en)
CA (1) CA2223625C (en)
CO (1) CO4700453A1 (en)
CZ (1) CZ289233B6 (en)
DE (1) DE69522718T2 (en)
DK (1) DK0832066T3 (en)
DZ (1) DZ2036A1 (en)
ES (1) ES2161291T3 (en)
FI (1) FI974437A (en)
GR (1) GR3037075T3 (en)
HR (1) HRP960266B1 (en)
HU (1) HUP9601285A3 (en)
IL (1) IL118236A0 (en)
IS (1) IS1846B (en)
LV (1) LV11614B (en)
MA (1) MA23874A1 (en)
MX (1) MX9709874A (en)
NO (1) NO307335B1 (en)
NZ (1) NZ286736A (en)
OA (1) OA10459A (en)
PL (1) PL314603A1 (en)
PT (1) PT832066E (en)
RU (1) RU2159613C2 (en)
SG (1) SG45481A1 (en)
SI (1) SI9600163A (en)
SK (1) SK72096A3 (en)
TN (1) TNSN96075A1 (en)
TR (1) TR199600478A1 (en)
TW (1) TW450961B (en)
WO (1) WO1996039385A1 (en)
YU (1) YU34796A (en)
ZA (1) ZA964646B (en)

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0832066T3 (en) * 1995-06-06 2001-11-19 Pfizer Substituted N- (indole-2-carbonyl) amides and derivatives as glycogen phosphorylase inhibitors
US5952322A (en) * 1996-12-05 1999-09-14 Pfizer Inc. Method of reducing tissue damage associated with non-cardiac ischemia using glycogen phosphorylase inhibitors
CN100378118C (en) 1997-04-15 2008-04-02 Csir公司 Pharmaceutical compositions having appetite suppressant activity
CN1230171C (en) * 1997-06-18 2005-12-07 史密丝克莱恩比彻姆有限公司 Treating diabetes by thiazolidine-diketo and dimethylbiguanide
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
EP1741424B1 (en) 1997-08-11 2018-10-03 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailabilty
US6150378A (en) 1997-10-07 2000-11-21 Cephalon, Inc. Peptidyl-containing α-ketoamide cysteine and serine protease inhibitors
US6096778A (en) 1997-10-07 2000-08-01 Cephalon, Inc. α-ketoamide multicatalytic protease inhibitors
US6083944A (en) * 1997-10-07 2000-07-04 Cephalon, Inc. Quinoline-containing α-ketoamide cysteine and serine protease inhibitors
UA57811C2 (en) * 1997-11-21 2003-07-15 Пфайзер Продактс Інк. Compositions including aldose reductase inhibitors and glycogen phosphorylase inhibitors
AU766219B2 (en) 1998-02-02 2003-10-09 1149336 Ontario Inc. Method of regulating glucose metabolism, and reagents related thereto
US5998463A (en) * 1998-02-27 1999-12-07 Pfizer Inc Glycogen phosphorylase inhibitors
BR9910149A (en) * 1998-05-01 2001-10-02 Lilly Co Eli spla2 inhibitory ester
EP0978279A1 (en) * 1998-08-07 2000-02-09 Pfizer Products Inc. Inhibitors of human glycogen phosphorylase
US6686335B1 (en) 1998-09-22 2004-02-03 Cephalon, Inc. Hydroxamate-containing cysteine and serine protease inhibitors
BR0007532A (en) 1999-01-13 2001-11-20 Univ New York State Res Found Methods to identify protein kinase inhibitors, to test compounds for a capacity to inhibit protein kinase activity and to inhibit a protein kinase, non-peptide protein tyrosine kinase inhibitor, and, method of treating a condition responsive to a protein kinase inhibitor in a patient
US6239163B1 (en) 1999-03-15 2001-05-29 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6316489B1 (en) 1999-03-15 2001-11-13 Novo Nordisk A/S Salt of (2R,3R,4R)-3,4-dihydroxy-2-hydroxymethylpyrrolidine
US6410750B1 (en) 1999-06-18 2002-06-25 Pfizer Inc. Processes and intermediates for preparing 3(S)-[(5-chloro-1H-indole-2-carbonyl)-amino]-2(R)-hydroxy-4-phenyl-butyric acid
DK1088824T3 (en) * 1999-09-30 2004-04-13 Pfizer Prod Inc Bicyclic pyrrolylamides as glycogen phosphorylase inhibitors
GB2355657B (en) 1999-10-27 2004-07-28 Phytopharm Plc Inhibitors Of Gastric Acid Secretion
CZ20021492A3 (en) 1999-11-04 2003-06-18 Ortho-Mcneil Pharmaceutical, Inc. Non-peptidic substituted benzothiazepines functioning as vasopressin antagonists
ES2436610T3 (en) 2000-01-21 2014-01-03 Novartis Ag Combinations containing dipeptidylpeptidase-IV inhibitors and antidiabetic agents
CO5271699A1 (en) 2000-01-24 2003-04-30 Pfizer Prod Inc PROCEDURE FOR THE TREATMENT OF CARDIOMIOPATIA USING INHIBITORS OF THE GLUCOGENO FOSFORILASA
AU2001234114A1 (en) * 2000-02-24 2001-09-03 Takeda Chemical Industries Ltd. Drugs containing combined active ingredients
US6555569B2 (en) * 2000-03-07 2003-04-29 Pfizer Inc. Use of heteroaryl substituted N-(indole-2-carbonyl-) amides for treatment of infection
US6395767B2 (en) 2000-03-10 2002-05-28 Bristol-Myers Squibb Company Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
US20010053778A1 (en) * 2000-03-16 2001-12-20 Hoover Dennis J. Pharmaceutical compositions of glycogen phosphorylase inhibitors
US6562807B2 (en) * 2000-06-23 2003-05-13 Novo Nordisk A/S Glucagon antagonists/inverse agonists
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
IL144507A0 (en) * 2000-07-31 2002-05-23 Pfizer Prod Inc Use of glycogen phosphorylase inhibitors to inhibit tumor growth
US6746856B2 (en) 2000-08-09 2004-06-08 Pfizer Inc. Microbial conversion of bicyclic heteroaromatic compounds
WO2002036066A2 (en) * 2000-11-01 2002-05-10 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising organic vanadium complexes for treatment of ischemia
US6821960B2 (en) * 2000-11-17 2004-11-23 Noyo Nordisk Pharmaceuticals, Inc. Glucagon antagonists/inverse agonists
US20030037045A1 (en) * 2001-05-21 2003-02-20 Ian Melhado Distributed computing environment for recognition of proteomics spectra
US7005445B2 (en) 2001-10-22 2006-02-28 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors and methods for designing them
WO2003035621A1 (en) 2001-10-22 2003-05-01 The Research Foundation Of State University Of New York Protein kinase and phosphatase inhibitors, methods for designing them, and methods of using them
EP1452526A1 (en) * 2001-10-29 2004-09-01 Japan Tobacco Inc. Indole compound and medicinal use thereof
WO2003045228A2 (en) 2001-11-26 2003-06-05 Trustees Of Tufts College Methods for treating autoimmune disorders, and reagents related thereto
JP4771661B2 (en) 2001-11-26 2011-09-14 トラスティーズ オブ タフツ カレッジ Post-proline cleavage enzyme pseudopeptide inhibitor
HUP0500513A3 (en) * 2002-01-18 2006-07-28 Pfizer Prod Inc Intermediates for preparing glycogen phosphorylase inhibitors
MXPA04007433A (en) 2002-02-01 2004-10-11 Pfizer Prod Inc Method for making homogeneous spray-dried solid amorphous drug dispersions utilizing modified spray-drying apparatus.
MXPA03000966A (en) * 2002-02-28 2003-09-04 Pfizer Prod Inc Antidiabetic agents.
GB0205162D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205175D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205165D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205170D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205166D0 (en) * 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
GB0205176D0 (en) 2002-03-06 2002-04-17 Astrazeneca Ab Chemical compounds
DE10215908B4 (en) * 2002-04-11 2005-08-18 Aventis Pharma Deutschland Gmbh Acyl-3-carboxyphenyl-urea derivatives and their use as medicaments
IL164249A0 (en) * 2002-04-11 2005-12-18 Aventis Pharma Gmbh Acyl-3-carboxphenylurea derivatives, processes forpreparing them and their use
US6683106B2 (en) 2002-04-15 2004-01-27 Pfizer Inc. N-(indole-2-carbonyl)-b-alaninamide crystal forms
WO2003091213A1 (en) * 2002-04-25 2003-11-06 Yamanouchi Pharmaceutical Co., Ltd. Novel amide derivatives or salts thereof
US7057046B2 (en) 2002-05-20 2006-06-06 Bristol-Myers Squibb Company Lactam glycogen phosphorylase inhibitors and method of use
DE10225635C1 (en) * 2002-06-07 2003-12-24 Aventis Pharma Gmbh N-benzoylureido-cinnamic acid derivatives, process for their preparation and their use
JP4374428B2 (en) * 2002-07-11 2009-12-02 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Urea-substituted and urethane-substituted acylureas, processes for their preparation and their use as medicaments
UY27967A1 (en) * 2002-09-10 2004-05-31 Pfizer 2-HINDROXI-1,3-DIAMINOALCANE OIL
BR0316099A (en) * 2002-11-07 2005-09-27 Pfizer Prod Inc Antidiabetic Agents
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
FR2847471B1 (en) * 2002-11-25 2006-12-29 Expanscience Lab COMPOSITION COMPRISING AT LEAST ONE CARBAMIC ACID DERIVATIVE, ITS COSMETIC USE AND AS A MEDICINAL PRODUCT
JP2006519229A (en) 2003-02-13 2006-08-24 アルバート・アインシュタイン・カレッジ・オヴ・メディシン・オヴ・イェシヴァ・ユニヴァーシティ Regulation of food intake and glucose production by modulation of long-chain fatty acyl-CoA levels in the hypothalamus
US20040180845A1 (en) * 2003-03-13 2004-09-16 Newgard Christopher B. Methods and compositions for modulating glycogen synthesis and breakdown
EP1620427A1 (en) * 2003-04-17 2006-02-01 Pfizer Products Inc. Carboxamide derivatives as anti-diabetic agents
EP1633709A1 (en) * 2003-04-30 2006-03-15 Pfizer Products Inc. Anti-diabetic agents
CA2525502C (en) * 2003-05-21 2012-12-18 Prosidion Limited Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
EP1997533B8 (en) 2003-11-12 2014-10-29 Sino-Med International Alliance, Inc. Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors
US7576121B2 (en) 2003-11-12 2009-08-18 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7317109B2 (en) 2003-11-12 2008-01-08 Phenomix Corporation Pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
US7767828B2 (en) 2003-11-12 2010-08-03 Phenomix Corporation Methyl and ethyl substituted pyrrolidine compounds and methods for selective inhibition of dipeptidyl peptidase-IV
EP1768957A2 (en) * 2004-03-08 2007-04-04 Prosidion Ltd. Indole-2-carboxylic acid hydrazides as glycogen phosphorylase inhibitors
DE602005023965D1 (en) 2004-03-08 2010-11-18 Prosidion Ltd PYRROLOPYRIDINE-2-CARBOXYLIC HYDRAZIDE AS INHIBITORS OF GLYCOPE PHOSPHORYLASE
EP1778220A1 (en) 2004-07-12 2007-05-02 Phenomix Corporation Constrained cyano compounds
US7365061B2 (en) 2004-11-15 2008-04-29 Bristol-Myers Squibb Company 2-Amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7214704B2 (en) 2004-11-15 2007-05-08 Bristol-Myers Squibb Company 2-Amino-1-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
US7223786B2 (en) 2004-11-15 2007-05-29 Bristol-Myers Squibb Company 2-aminonaphthalene derivatives and related glycogen phosphorylase inhibitors
WO2006055462A1 (en) 2004-11-15 2006-05-26 Bristol-Myers Squibb Company 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors
WO2006059163A1 (en) * 2004-12-02 2006-06-08 Prosidion Limited Treatment of diabetes with glycogen phosphorylase inhibitors
US7825139B2 (en) 2005-05-25 2010-11-02 Forest Laboratories Holdings Limited (BM) Compounds and methods for selective inhibition of dipeptidyl peptidase-IV
PL1931350T5 (en) 2005-09-14 2021-11-15 Takeda Pharmaceutical Company Limited Administration of dipeptidyl peptidase inhibitors
US7741317B2 (en) 2005-10-21 2010-06-22 Bristol-Myers Squibb Company LXR modulators
US7888376B2 (en) 2005-11-23 2011-02-15 Bristol-Myers Squibb Company Heterocyclic CETP inhibitors
WO2007090068A2 (en) * 2006-01-27 2007-08-09 Fibrogen, Inc. Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
PE20080251A1 (en) 2006-05-04 2008-04-25 Boehringer Ingelheim Int USES OF DPP IV INHIBITORS
US7838542B2 (en) 2006-06-29 2010-11-23 Kinex Pharmaceuticals, Llc Bicyclic compositions and methods for modulating a kinase cascade
DE102006042147A1 (en) * 2006-09-06 2008-03-27 Dynamit Nobel Gmbh Explosivstoff- Und Systemtechnik Hydrochlorides of 3-amino-2-hydroxycarboxylic acid amides
US20100179131A1 (en) 2006-09-07 2010-07-15 Nycomed Gmbh Combination treatment for diabetes mellitus
NZ575603A (en) * 2006-09-13 2011-03-31 Sanofi Aventis ISOSERINE DERIVATIVES FOR USE AS COAGULATION FACTOR IXa INHIBITORS
WO2008070496A2 (en) 2006-12-01 2008-06-12 Bristol-Myers Squibb Company N- ( (3-benzyl) -2, 2- (bis-phenyl) -propan-1-amine derivatives as cetp inhibitors for the treatment of atherosclerosis and cardiovascular diseases
ES2371393T3 (en) 2007-03-12 2011-12-30 Zadec Aps ROOIBOS ANTIDIABETIC EXTRACT.
CN102123990B (en) 2008-06-19 2014-07-09 武田药品工业株式会社 Heterocyclic compound and use thereof
CR20170089A (en) 2009-04-03 2017-07-17 Plexxikon Inc PROPANE-ACID COMPOSITIONS-1 - SULFONIC {3- [5- (4-CHLORINE-PHENYL) -1H-PIRROLO [2,3-B] PIRIDINA-3-CARBONIL] -2,4-DIFLUORO-PHENIL} -AMIDA AND THE USE OF THE SAME
WO2011041293A1 (en) 2009-09-30 2011-04-07 Takeda Pharmaceutical Company Limited Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors
CA2787360C (en) 2010-02-03 2019-03-05 Takeda Pharmaceutical Company Limited Pyrrol0[3,2-c]pyridinyl-4-benzamide compounds and their use as apoptosis signal-regulating kinase 1 inhibitors
US20130072519A1 (en) 2010-05-21 2013-03-21 Edward Lee Conn 2-phenyl benzoylamides
US20130345392A1 (en) 2011-03-04 2013-12-26 Pfizer Inc Edn3-like peptides and uses thereof
WO2012166390A1 (en) * 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
CN103748070B (en) 2011-05-31 2015-06-24 施万生物制药研发Ip有限责任公司 Neprilysin inhibitors
CA2835216A1 (en) 2011-05-31 2012-12-06 Theravance, Inc. Neprilysin inhibitors
US20150050371A1 (en) 2012-03-09 2015-02-19 Biotropics Malaysia Berhad Extract Formulations of Rhodamnia Cinerea And Uses Thereof
EP2986599A1 (en) 2013-04-17 2016-02-24 Pfizer Inc. N-piperidin-3-ylbenzamide derivatives for treating cardiovascular diseases
CN103497181B (en) 2013-09-30 2016-03-30 承德医学院 As the benzazepine ketone compounds of glycogen phosphorylase inhibitors, its preparation method and medicinal use
JP6657101B2 (en) 2013-11-05 2020-03-04 ベン グリオン ユニバーシティ オブ ザ ネガフ リサーチ アンド ディベロップメント オーソリティ Compounds for the treatment of diabetes and disease complications resulting therefrom
US10925881B2 (en) * 2014-02-28 2021-02-23 Tensha Therapeutics, Inc. Treatment of conditions associated with hyperinsulinaemia
WO2016055901A1 (en) 2014-10-08 2016-04-14 Pfizer Inc. Substituted amide compounds
US11248001B2 (en) 2019-01-18 2022-02-15 Astrazeneca Ab PCSK9 inhibitors and methods of use thereof
CN115583908A (en) * 2021-07-05 2023-01-10 西北农林科技大学 Indole carboxamide compound and preparation method and application thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4836846A (en) 1981-07-16 1989-06-06 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
US4764610A (en) 1981-07-16 1988-08-16 E. I. Du Pont De Nemours And Company Herbicidal indole sulfonamides
NZ202232A (en) 1981-11-06 1985-08-16 Smithkline Beckman Corp N-carboxyalkylproline-containing tripeptides and pharmaceutical compositions
US4933325A (en) 1985-08-14 1990-06-12 G. D. Searle & Co. Pyridyl and pyrimidinyl substituted tyrosyl dipeptide amides
US4902708A (en) 1985-12-31 1990-02-20 Biomeasure, Inc. CCK antagonists
US5089638A (en) 1986-06-16 1992-02-18 Merck & Co., Inc. Amino acid analogs as CCK-antagonists
US5034376A (en) 1986-10-31 1991-07-23 Pfizer Inc. Nor-statine and nor-cyclostatine polypeptides
HU204285B (en) 1986-10-31 1991-12-30 Pfizer Process for producing renin-inhibiting polypeptides of small molecule mass and pharmaceutical compositions containing them
EP0288965A2 (en) 1987-04-29 1988-11-02 Hoechst Aktiengesellschaft Peptides with a phospholipase A2 inhibiting activity
US5128346A (en) 1987-09-21 1992-07-07 Abbott Laboratories Derivatives of D-glutamic acid and D-aspartic acid
US5250517A (en) 1987-10-06 1993-10-05 Hoffmann-La Roche Inc. Renin inhibiting compounds
EP0336356A3 (en) 1988-04-05 1991-09-25 Abbott Laboratories Derivatives of tryptophan as cck antagonists
US5346907A (en) 1988-04-05 1994-09-13 Abbott Laboratories Amino acid analog CCK antagonists
US4904846A (en) 1988-04-29 1990-02-27 Augustin Oscadal Oil filled body heater
US5010089A (en) 1988-08-12 1991-04-23 Biomeasure, Inc. CCK antagonists and their use in treating gastrointestinal disorders
FR2643371B1 (en) 1989-02-17 1993-11-05 Roussel Uclaf NOVEL 2-AMINO PENTANEDIOIC ACID DERIVATIVES, THEIR PREPARATION PROCESS AND THEIR APPLICATION AS MEDICAMENTS
US4997950A (en) 1989-04-20 1991-03-05 Richard Finbar Murphy Novel C-terminal gastrin antagonists
IE902238A1 (en) 1989-06-30 1991-01-16 Abbott Lab Tetrapeptide type-b cck receptor ligands
IE902295A1 (en) 1989-07-07 1991-01-16 Abbott Lab Amino acid analog cck antagonists
IE66574B1 (en) 1989-12-04 1996-01-24 Searle & Co Heterocyclic acyl aminodiol beta-amino acid derivatives
AU639081B2 (en) 1990-02-09 1993-07-15 Rhone-Poulenc Rorer S.A. N-phenyl n-acetamido glycinamides, preparation method and drugs containing them
EP0518961A1 (en) 1990-03-07 1992-12-23 Aventis Pharma S.A. Derivatives of glycinamide, their preparation and medicaments containing them
FR2674522B1 (en) 1991-03-26 1993-07-16 Lipha NOVEL INDOLE DERIVATIVES, PREPARATION METHODS AND MEDICAMENTS CONTAINING THEM.
FR2678938B1 (en) 1991-07-10 1993-10-08 Rhone Poulenc Rorer Sa PYRROLIDINE DERIVATIVES, THEIR PREPARATION AND THE MEDICINAL PRODUCTS CONTAINING THEM.
GB9206757D0 (en) 1992-03-27 1992-05-13 Ferring Bv Novel peptide receptor ligands
WO1994006755A1 (en) 1992-09-18 1994-03-31 Japan Tobacco Inc. Alcohol derivative having renin-inhibiting activity and use thereof
WO1994007815A2 (en) 1992-09-25 1994-04-14 Abbott Laboratories Small peptide anaphylatoxin receptor ligands
DK0832066T3 (en) * 1995-06-06 2001-11-19 Pfizer Substituted N- (indole-2-carbonyl) amides and derivatives as glycogen phosphorylase inhibitors

Also Published As

Publication number Publication date
SK72096A3 (en) 1997-11-05
HRP960266A2 (en) 1997-08-31
RU2159613C2 (en) 2000-11-27
AP9600816A0 (en) 1996-07-31
NO962322D0 (en) 1996-06-05
EP0832066A1 (en) 1998-04-01
DE69522718T2 (en) 2002-02-07
CN1374082A (en) 2002-10-16
SI9600163A (en) 1997-02-28
AP624A (en) 1997-12-19
DK0832066T3 (en) 2001-11-19
AU5475396A (en) 1996-12-19
GR3037075T3 (en) 2002-01-31
PT832066E (en) 2001-12-28
ATE205477T1 (en) 2001-09-15
EP0832066B1 (en) 2001-09-12
IL118236A0 (en) 1996-09-12
NZ286736A (en) 2001-07-27
CZ162796A3 (en) 1996-12-11
TNSN96075A1 (en) 2005-03-15
AP9600817A0 (en) 1996-07-31
FI974437A0 (en) 1997-12-05
HRP960266B1 (en) 2002-08-31
MA23874A1 (en) 1996-12-31
DE69522718D1 (en) 2001-10-18
US6297269B1 (en) 2001-10-02
TW450961B (en) 2001-08-21
JP3068200B2 (en) 2000-07-24
AU700887B2 (en) 1999-01-14
DZ2036A1 (en) 2002-10-22
JPH11500445A (en) 1999-01-12
NO962322L (en) 1996-12-09
CA2223625C (en) 2003-06-03
BG100635A (en) 1997-09-30
CZ289233B6 (en) 2001-12-12
LV11614B (en) 1997-04-20
SG45481A1 (en) 1998-01-16
BR9602626A (en) 1998-09-01
ES2161291T3 (en) 2001-12-01
WO1996039385A1 (en) 1996-12-12
NO307335B1 (en) 2000-03-20
PL314603A1 (en) 1996-12-09
ZA964646B (en) 1997-12-05
YU34796A (en) 1999-07-28
BG62566B1 (en) 2000-02-29
FI974437A (en) 1997-12-05
HUP9601285A3 (en) 2001-04-28
LV11614A (en) 1996-12-20
CO4700453A1 (en) 1998-12-29
OA10459A (en) 2002-03-27
IS1846B (en) 2003-02-07
IS4345A (en) 1996-12-07
HU9601285D0 (en) 1996-07-29
HUP9601285A2 (en) 1998-09-28
TR199600478A1 (en) 1997-03-21
MX9709874A (en) 1998-03-31

Similar Documents

Publication Publication Date Title
CA2223625A1 (en) Substituted n-(indole-2-carbonyl-) amides and derivatives as glycogen phosphorylase inhibitors
AU6645998A (en) Oxygen or sulfur containing heteroaromatics as factor xa inhibitors
DE69531502D1 (en) MONOAMIDE, DIAMIDE, THIOL CONTAINING METAL-CHELATING COMPOUNDS
RU95101048A (en) Prolineamide derivatives and pharmcomposition based thereon
AU4064597A (en) Amidinophenyl-pyrrolidines, -pyrrolines, and -isoxazolidines and derivatives thereof
CA2216796A1 (en) Quinazoline derivatives
EP0826671A4 (en) Heterocyclic amide compounds and medicinal use of the same
EP1090908A3 (en) Cyclobutane derivatives as inhibitors of protein farnesyltransferase
NO20031024L (en) Bicyclic pyrrolyl amides as glucogenic phosphorylase inhibitors
MY132473A (en) Crystalline hydrochloride of (r)-(-)-2-&lt;n-[4-(1,1- dioxido-3-oxo-2,3-dihydro-benzisothiazol-2-yl)-butyl]-aminomethyl&gt;-chroman
MX9709416A (en) Quinolizinone type compounds.
CA2260213A1 (en) Pyridylpyrrole compounds useful as interleukin- and tnf antagonists
WO1994020063A3 (en) Pharmaceutical tryptophan containing dipeptide compositions and methods of use thereof
BG103947A (en) Derivatives of 9-oxymerythromycin
NO984470L (en) Pyrrolopyrrolone derivatives as inhibitors of neutrophil elastase
AU4696897A (en) Neurotrophin antagonist compositions
EP0807633A3 (en) Novel 2,3-disubstituted-(5,6)- heteroarylfused-pyrimidine-4-ones
WO2000039083A3 (en) Pyrazole compounds and uses thereof
BR9503572A (en) Compound pharmaceutical composition and method of treatment or prevention of a disease
CA2282279A1 (en) Atropisomers of 3-heteroaryl-4(3h)-quinazolinones for the treatment of neurodegenerative and cns-trauma related conditions
HK1068332A1 (en) Pyrane derivatives as both ace-and nep-inhibitors
IL131216A (en) Drugs inhibiting progress of pterygium and postoperative recurrence of the same
NO934760D0 (en) Aryl-substituted heterocyclic compounds
NO982863L (en) New compounds with analgesic effect
DK0604355T3 (en) Aryl-substituted heterocyclic compounds

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed